Details

Pojavnost enterobakterij, ki izločajo karbapenemaze, v Sloveniji med letoma 2017 in 2022
ID Pirš, Mateja (Author), ID Kramar, Urška (Author), ID Ribič, Helena (Author), ID Kavka, Daša (Author), ID Seme, Katja (Author), ID Velimirović, Ivana (Author), ID Križan-Hergouth, Veronika (Author), ID Švent-Kučina, Nataša (Author), ID Maver Vodičar, Polona (Author), ID Zdolšek, Barbara (Author), ID Bombek, Maja (Author), ID Žohar Čretnik, Tjaša (Author), ID Berce, Ingrid (Author), ID Jeverica, Samo (Author), ID Juriševič Dodič, Anamarija (Author), ID Tomič, Viktorija (Author), ID Stojoska Surbanovska, Tanja (Author), ID Piltaver-Vajdec, Irena (Author), ID Štrumbelj, Iztok (Author)

.pdfPDF - Presentation file, Download (645,60 KB)
MD5: ED13225CBD802F9366CEC8F9B3D79714
URLURL - Source URL, Visit https://imi.si/meetings/14-banicevi-dnevi-okuzbe-povezane-z-zdravstvom-in-veckratno-odporne-bakterije/?utm_source This link opens in a new window

Abstract
Izhodišča: Naraščanje števila okužb s proti karbapenemom odpornimi enterobakterijami, ki izločajo karbapenemaze (CRE-CPE), oziroma z enterobakterijami, ki izločajo karbapenemaze (CPE), je resen javnozdravstveni izziv. Zdravljenje je težavno, saj so izolati odporni proti vsem ali večini betalaktamov, specifične kombinacije zaviralcev karbapenemaz z betalaktami so na voljo le za nekatere serinske karbapenemaze, specifičnih zaviralcev metalobetalaktamaz še ni v klinični rabi. Pogosto so ti izolati odporni tudi proti drugim antibiotičnim razredom, kar resno otežuje zdravljenje. Metode: Iz laboratorijskih informacijskih sistemov mikrobioloških laboratorijev iz vseh slovenskih regij smo zbrali podatke o številu pacientov z izolati CRE- -CPE/CPE, osamljenimi iz kliničnih in nadzornih kužnin med letoma 2017 in 2022. Rezultati: Analiza pojavnosti CRE-CPE/CPE je pokazala pomembne razlike v pojavnosti med enterobakterijami in pomembno naraščanje CRE-CPE/CPE v zadnjih šestih letih. V kliničnih kužninah smo med CRE-CPE/CPE najpogosteje našli izolate vrste Klebsiella pneumoniae (166 pacientov), sledile so vrste rodov Citrobacter (58 pacientov), Enterobacter (45 pacientov) in izolati vrste Escherichia coli (31 pacientov). Delež K. pneumoniae – CRE-CPE/CPE in E. coli – CRE-CPE/CPE je ves čas naraščal (število izolatov je bilo v letu 2022 6- oziroma 5,5-krat višje kot v letu 2017). Breme CRE-CPE/CPE iz kliničnih kužnin je naraslo z 0,3/100.000 prebivalcev v letu 2017 na 1,1/100.000 prebivalcev v letu 2022. Bistveno večje število pacientov z izolati CRE-CPE/CPE (povprečno 69,7 %) smo odkrili samo iz nadzornih kužnin. Skupno breme CRE-CPE/CPE iz kliničnih in nadzornih kužnin se je povečalo z 0,6/100.000 prebivalcev v letu 2017 na 3,4/100.000 prebivalcev v letu 2022, z najvišjim deležem pri K. pneumoniae – CRE-CPE/CPE, in sicer 7/100.000 prebivalcev. Zaključki: V letih 2017–2022 se je nekajkrat povečalo število pacientov s CRE- -CPE/CPE. Ustrezna mikrobiološka diagnostika, smotrna raba antibiotikov in regionalni ukrepi bolnišnične higiene brez nacionalnega sistema ne zadostujejo. Kritično je redno spremljanje trendov odpornosti, sledenje bolnikom, ki so kolonizirani ali okuženi s CRE-CPE/CPE, tako v bolnišničnem kot tudi v domačem okolju, ter izvajanje ustreznih lokalnih in nacionalnih ukrepov, ki se morajo nenehno prilagajati novim epidemiološkim okoliščinam.

Language:Slovenian
Keywords:enterobakterije, ki so odporne proti karbapenemom – CRE, CRE-CPE: oboje, CRE in CPE, Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Citrobacter spp.
Work type:Article
Typology:1.08 - Published Scientific Conference Contribution
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2024
Number of pages:Str. 71-86
PID:20.500.12556/RUL-191219 This link opens in a new window
UDC:579.6
COBISS.SI-ID:202524419 This link opens in a new window
Publication date in RUL:12.11.2026
Views:10
Downloads:0
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a monograph

Title:14. Baničevi dnevi : Okužbe, povezane z zdravstvom, in večkratno odporne bakterije
Editors:Tadeja Matos
Place of publishing:Ljubljana
Publisher:Sekcija za mikrobiologijo in bolnišnične okužbe SZD
Year:2024
ISBN:978-961-7092-65-3
COBISS.SI-ID:199265795 This link opens in a new window

Secondary language

Language:English
Title:Incidence of carbapenemase-producing enterobacteria in Slovenia, 2017–2022
Abstract:
Background: Increasing incidence of carbapenem resistant carbapenemase-producing enterobacteria (CRE-CPE) and carbapenemase-producing enterobacteria (CPE), known as CRE-CPE / CPE, pose a significant public health challenge. Treatment is complicated as these isolates are resistant to most beta-lactam antibiotics. Specific combinations with carbapenemase inhibitors are only effective against certain serine carbapenemases, there are no specific inhibitors for metallo-beta-lactamases currently in clinical use. CRE-CPE / CPE isolates are usually resistant to other antibiotic classes further reducing treatment options. Methods: Data on the number of patients with CRE-CPE / CPE isolates were collected from laboratory information systems from microbiology laboratories in all Slovenian regions, isolated from clinical and surveillance specimens between 2017 and 2022. Results: There were significant variations in the prevalence of CRE-CPE / CPE, with a notable increase over the past six years. Klebsiella pneumoniae (166 patients) was most frequent CRE-CPE / CPE isolate from clinical samples, followed by Citrobacter spp. (58 patients), Enterobacter spp. (45 patients), and Escherichia coli (31 patients). The proportion of K. pneumoniae – CRE-CPE / CPE and E. coli – CRE-CPE / CPEsteadily rose (6- and 5.5-fold higher incidence, respectively) in 2022 than in 2017. The burden of CRE-CPE / CPE in clinical specimens increased from 0.3/100,000 inhabitants in 2017 to 1.1/100,000 inhabitants in 2022. Majority of CRE-CPE / CPE patients (on average 69.7 %) we found only through surveillance samples. Total burden of CRE-CPE / CPE from clinical and surveillance samples increased from 0.6/100.000 inhabitants in 2017 to 3.4/100.000 inhabitants in 2022, the highest burden represented K. pneumoniae CRE-CPE CPE with 7/100.000 inhabitants. Conclusions: There has been a substantial increase in patients with CRE-CPE / CPE isolates in Slovenia in the past 6 years. Optimal microbiological diagnostics, prudent antibiotic use, and regional hospital hygiene measures, without a national system within and outside healthcare facilities, are insufficient. Regular monitoring of resistance trends, tracking colonized or infected patients in both hospital and community settings, and implementing appropriate local and national measures are crucial and should continually adapt to evolving epidemiological circumstances.

Keywords:Carbapenem-Resistant Enterobacteriaceae – CRE

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back